Key facts
- This page summarizes Michael H. May's Form 4 filing for AgeX Therapeutics, Inc. (SER).
- 2 reported transactions and 2 derivative rows are listed below.
- Accepted by SEC: 23 Jun 2021, 21:46.
Michael H. May - 21 Jun 2021 Form 4 Insider Report for AgeX Therapeutics, Inc. (SER)
- Reporting relationship
- Director
- Issuer ticker
- SER
- Reported as of
- 21 Jun 2021
- Net transaction value
- $0
- Reporting owner signature
- /s/Michael H. May
Source evidence
Original filing metadata and source links for verification.
3 source fields
Reporting owner
1 detail
Filing notes and source
Key filing fact
Michael H. May filed Form 4 for AgeX Therapeutics, Inc. (SER) on 23 Jun 2021.
Change
- No earlier filing in this sequence is available for direct comparison.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
AGE
transaction
Derivative
Option to Purchase Common Stock
Award
- Transaction value
- $0
- Shares
- +65,000
- Change %
- Price
- $0.000000
- Shares after
- 65,000
- Date
- 21 Jun 2021
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 65,000
- Exercise price
- $1.48
- Footnotes
- F1
AGE
transaction
Derivative
Option to Purchase Common Stock
Award
- Transaction value
- $0
- Shares
- +35,000
- Change %
- Price
- $0.000000
- Shares after
- 35,000
- Date
- 21 Jun 2021
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 35,000
- Exercise price
- $1.48
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 1 footnote
Footnote F1
Options will vest and become exercisable in four equal quarterly installments on June 30, 2021, September 30, 2021, December 31, 2021, and March 31, 2022, provided that the grantee remains a director on the last day of the applicable calendar quarter.